Attenuation of soft-tissue sarcomas resistance to the cytotoxic action of TNF-α by restoring p53 function.
BACKGROUND
Isolated limb perfusion with TNF-α and melphalan is used with remarkable efficiency to treat unresectable limb sarcomas. Here we tested the ability of TNF-α to directly induce apoptosis of sarcoma cells. In addition, we investigated the impact of p53 in the regulation of such effect.


RESULTS
We first analysed the ability of TNF-α to induce apoptosis in freshly isolated tumour cells. For this purpose, sarcoma tumours (n = 8) treated ex vivo with TNF-α were processed for TUNEL staining. It revealed substantial endothelial cell apoptosis and levels of tumour cell apoptosis that varied from low to high. In order to investigate the role of p53 in TNF-α-induced cell death, human sarcoma cell lines (n = 9) with different TP53 and MDM2 status were studied for their sensitivity to TNF-α. TP53(Wt) cell lines were sensitive to TNF-α unless MDM2 was over-expressed. However, TP53(Mut) and TP53(Null) cell lines were resistant. TP53 suppression in TP53(Wt) cell lines abrogated TNF-α sensitivity and TP53 overexpression in TP53(Null) cell lines restored it. The use of small molecules that restore p53 activity, such as CP-31398 or Nutlin-3a, in association with TNF-α, potentiated the cell death of respectively TP53(Mut) and TP53(Wt)/MDM2(Ampl). In particular, CP-31398 was able to induce p53 as well as some of its apoptotic target genes in TP53(Mut) cells. In TP53(Wt)/MDM2(Ampl) cells, Nutlin-3a effects were associated with a decrease of TNF-α-induced NF-κB-DNA binding and correlated with a differential regulation of pro- and anti-apoptotic genes such as TP53BP2, GADD45, TGF-β1 and FAIM.


CONCLUSIONS
More effective therapeutic approaches are critically needed for the treatment of unresectable limb sarcomas. Our results show that restoring p53 activity in sarcoma cells correlated with increased sensitivity to TNF-α, suggesting that this strategy may be an important determinant of TNF-α-based sarcomas treatment.
Unité INSERM U753, Institut de Cancérologie Gustave Roussy, Villejuif, France. muret@igr.fr
Jane
J
Muret
Meriem
M
Hasmim
Izabela
I
Stasik
Abdelali
A
Jalil
Aude
A
Mallavialle
Arash
A
Nanbakhsh
Ludovic
L
Lacroix
Katy
K
Billot
Véronique
V
Baud
Jérome
J
Thiery
Philippe
P
Vielh
Philippe
P
Terrier
Joelle
J
Wiels
Lyubomir
L
Vassilev
Axel
A
Lecesne
Sylvie
S
Bonvalot
Salem
S
Chouaib
D017209:Apoptosis; D015153:Blotting, Western; D045744:Cell Line, Tumor; D005434:Flow Cytometry; D016158:Genes, p53; D006801:Humans; D020287:In Situ Nick-End Labeling; D009154:Mutation; D060888:Real-Time Polymerase Chain Reaction; D012509:Sarcoma / Q000473:pathology / Q000503:physiopathology*; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology*
D014409:Tumor Necrosis Factor-alpha